ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 327 for:    Recruiting, Not yet recruiting, Available Studies | "Chronic Pain"

Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03337503
Recruitment Status : Recruiting
First Posted : November 9, 2017
Last Update Posted : January 31, 2018
Sponsor:
Collaborator:
Tetra Bio-Pharma
Information provided by (Responsible Party):
Santé Cannabis

Brief Summary:
Seeking for effective therapeutic strategies, the investigators are proposing to test the effectiveness of different formulations of medical cannabis oil to alleviate chronic pain, which was partially relieved with conventional prescriptions. Furthermore, the investigators would like to assess the effect of different formulations of medical cannabis oil on other symptoms associated to chronic pain like anxiety and depression, as well as insomnia and appetite. Finally, as recently recommended for clinical studies on medical cannabis, the investigators will examine the safety profile of different cannabis formulations focusing on the following elements: a real chronic administration with more than two weeks of treatment, a larger number of patients, and the clinical relevance of medical cannabis oil to change the amount and type of concomitant medications used to control chronic non-cancer and cancer pain.

Condition or disease Intervention/treatment Phase
Chronic Pain Drug: THC and CDB in a 1 to 1 ratio Drug: Experimental: THC and CBD in a 1 to 2 ratio Drug: High CBD with trace THC oil Other: placebo Phase 4

Detailed Description:

This is a 6-week randomized, double-blind, placebo-controlled, parallel group design trial followed by an open-label extension phase of 12 weeks, to evaluate the safety and efficacy of different formulations of medical cannabis oil to reduce chronic pain intensity.

The study will be conducted at Santé Cannabis Clinic, the only medical cannabinoid therapy clinic, located in Montreal, Quebec. One hundred and sixty consecutive adult patients, male and female, with chronic non-cancer and cancer pain (at least 3 months in duration), with an average weekly pain intensity score greater than 4 on the 11 points NRS, will be prospectively recruited and invited to participate in this trial.

Informed consent will be obtained by a Research Assistant.

After baseline documentation with standardized scales, patients will be randomized to one of 4 parallel groups:

  • Group A: THC/CBD ratio 1:1 capsule
  • Group B: THC/CBD ratio 1:2 capsule
  • Group C: THC/CBD ratio 0.1:2 capsule
  • Group D: Placebo capsule Patients will have a dose titration phase during the first week. The dose escalation will allow patients to adapt to the potential adverse effects (AEs) of the medical cannabis.

Follow-up visits will be done after 1 week and 6 weeks of treatment. At the end of the first phase of the study, patients who wish to participate in the open-label extension phase will have the option to continue in the same treatment regimen. For the placebo group, the investigator may propose one of the cannabis oils to the subject if they feel it may potentially provide benefits.

They will take this new treatment for other 12 weeks. For this open-label extension phase the follow-up visits will be done after 4 weeks and 12 weeks of treatment.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Pilot Study, Followed by an Open-Label Extension Phase
Actual Study Start Date : January 29, 2018
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: THC and CDB in a 1 to 1 ratio

Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.

2.5 mg THC with 2.5 mg CBD capsule

Drug: THC and CDB in a 1 to 1 ratio
capsule containing cannabis oil

Experimental: THC and CBD in a 1 to 2 ratio

Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.

2.5 mg THC with 5 mg CBD capsule

Drug: Experimental: THC and CBD in a 1 to 2 ratio
capsule containing cannabis oil

Experimental: high CBD with trace THC

Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.

20 mg CBD with traces of THC

Drug: High CBD with trace THC oil
capsule containing cannabis oil

Placebo Comparator: placebo

Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.

carrier oil capsule

Other: placebo
carrier oil capsule




Primary Outcome Measures :
  1. Does the daily use of cannabis oil improves chronic pain [ Time Frame: Change from Baseline in BPI-SF at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in pain as measured by the Brief Pain Inventory-Short Form (BPI-SF) scale. Scale range is 0 to 10; 0 (No pain) being the best rating to the maximal rating of 10 (Pain as bad as you can imagine).

  2. Does the daily use of cannabis oil improves chronic pain [ Time Frame: Change from Baseline in NRS at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in pain as measured by the Numerical Rating Scale (NRS). The NRS is a measure of the average weekly pain intensity score greater than on a 0 to 10 points scale where 0 is No Pain and 10 is the worst pain.


Secondary Outcome Measures :
  1. Does the daily use of cannabis oil improve symptom burden [ Time Frame: Change from Baseline in ESAS-r-CS at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in symptom burden as measured by the revised Edmonton Symptom Assessment System version with Constipation and Sleep was added to assess improvement in symptom burden (ESAS-r-CS). Scale range is 0 to 10; 0 (No symptom) being the best rating to the maximal rating of 10 (Worst possible score for symptom).

  2. Does the daily use of cannabis oil reduce the severity of Treatment-Emergent Adverse Events (safety and tolerability). [ Time Frame: Change from Baseline in UKU-SERSP at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in validated UKU Side Effects Rating Scale for Patients (UKU-SERS-Pat). Scale range is 0 to 3 for rating the degree of severity and a second scale for the investigator that assigns a casual relationship of improbable, possible or probable.

  3. Does the daily use of cannabis oil improve cognition [ Time Frame: Change from Baseline in Mini-Cog at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in validated Mini-Cog. Scale range is numerical and rates the ability to recall words and ability to draw a clock showing numbers from 1 to 12 and then drawing the given time.

  4. Does the daily use of cannabis oil reduce the Profile of Mood States (POMS) [ Time Frame: Change from Baseline in POMS at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in POMS . Scale range is 1 to 5 and describes how you feel right now. Scale of 1, the lowest score, describes a feeling of Not At All right now for the mood and the scale of 5 gives the highest score representing a feeling of Extremely for the mood.

  5. Does the daily use of cannabis oil improve the Hamilton Rating Scale for Depression (HAM-D) [ Time Frame: Change from Baseline in HAM-D at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in HAM-D scale. Scale range is either 0 to 2 or 0 to 4. The scale is designed to rate the severity of depression with a score of 0 representing the absence of the question and 2 or 4 meaning the highest severity.

  6. Does the daily use of cannabis oil improve Medication Quantification Scale (MQS) version III [ Time Frame: Change from Baseline in MQS version III at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18. ]
    Changes in concurrent medications, rescue medications and Medication Quantification Scale (MQS) version III. MQS is a method of quantifying different pain drug regimens by evaluating the use of 22 distinct drug classes (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], antidepressants, benzodiazepines, opiates). A single value is calculated based on a patient's pain medication profile, taking into account dosages, and the types of pain medications prescribed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent
  2. Adult patients (older than 18 years of age), male and female, with chronic non-cancer and cancer pain (at least 3 months in duration)
  3. Patients experiencing an average weekly pain intensity score greater than 4 on a 11 points NRS
  4. Subject agreed to follow the protocol
  5. Naïve cannabis patients with chronic non-cancer and cancer pain (not used cannabis in any presentation in the last 12 weeks)
  6. Patients receiving opioids and other concomitant pain medications should have a stable dose for the last 15 days.
  7. Normal cognitive status according to MiniCog
  8. Normal liver function (defined as aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L)
  9. Normal renal function (defined as serum creatinine level <133 µmol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60)
  10. Negative result on βhuman chorionic gonadotropin pregnancy test (if applicable)
  11. Ability to read and respond to questions in French or English.
  12. A female volunteer must meet one of the following criteria:

    If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 28 days prior to the first drug administration, during the study and for at least 60 days after the last dose.

    If of non-childbearing potential - should be surgically sterile or in a menopausal state

  13. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.

Exclusion Criteria:

  1. Acute pain (less than 3 months in duration)
  2. Previous serious adverse event or hypersensitivity to cannabis or cannabinoids
  3. Inability to understand and comply with the instructions of the study
  4. Presence of significant cardiac disease (history of unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension) that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction
  5. Current substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)
  6. Life-time history of dependence on cannabis or diagnosis of cannabis use disorder (CUD) according to the DSM 5
  7. Life-time history of DSM 5 schizophrenia, bipolar disorder, or previous psychosis with or intolerance to cannabinoids
  8. Current or history of suicidal ideation
  9. Pregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception
  10. Hepatic impairment (aspartate aminotransferase more than three times normal) or renal function impairment (serum creatinine level >133 µmol/L, Estimated Glomerular Filtration Rate (eGFR) <60)
  11. Cognitive impairment according to MiniCog
  12. The patient is currently using or has used cannabinoid based medications within 90 days of study entry and is unwilling to abstain for the duration of the study
  13. Positive urine drug screen for cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)
  14. Participation in another clinical trial within 30 days of enrolment in our trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03337503


Contacts
Contact: Erin Prosk, MSc (514) 419-4131 erin@santecannabis.ca
Contact: Maria Fernanda Arboleda, MD (514) 419-4131 mfarboleda@santecannabis.ca

Locations
Canada, Quebec
Santé Cannabis Recruiting
Montréal, Quebec, Canada, H2L 3K9
Contact: Erin Prosk    514-419-4131    erin@santecannabis.ca   
Sponsors and Collaborators
Santé Cannabis
Tetra Bio-Pharma
Investigators
Principal Investigator: Antonio Vigano, MD, MSc McGill University
Study Director: Maria Fernanda Arboleda, MD McGill University

Responsible Party: Santé Cannabis
ClinicalTrials.gov Identifier: NCT03337503     History of Changes
Other Study ID Numbers: Cannabis Oil Study PPP005-001
First Posted: November 9, 2017    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Chronic Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms